Form 4: Aquestive COO Exercises Options, Sells Shares
Insider Transaction Report
Aquestive Therapeutics' Chief Operating Officer, Cassie Jung, executed a pre-planned transaction, exercising stock options and selling common stock.
Summary
- Cassie Jung, Chief Operating Officer of Aquestive Therapeutics, Inc., engaged in pre-planned transactions on September 4, 2025, under a Rule 10b5-1 trading plan.
- Exercised 25,000 non-qualified stock options at an exercise price of $3.15 per share.
- Exercised another 25,000 non-qualified stock options at an exercise price of $0.7063 per share.
- Sold 62,180 shares of common stock at a price of $5.00 per share.
- Following these transactions, Cassie Jung beneficially owns 283,346 shares of common stock directly.
- An additional 2,000 shares are indirectly owned by her spouse.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions (option exercises and sales) executed under a pre-planned 10b5-1 program. This is generally neutral news, as it reflects personal financial planning rather than a direct statement on company performance or outlook.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-determined approach to managing equity.
- The sale price of $5.00 per share is significantly higher than the exercise prices of $3.15 and $0.7063, indicating a profitable transaction for the insider.
Negatives
- The sale of 62,180 shares by a Chief Operating Officer could be interpreted as a reduction in direct exposure to the company's stock, although it is part of a pre-planned strategy.
Management Comments
- This is a scheduled exercise from 10b5-1 trading plan.
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person.
- The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
Related Party Transactions
- 2,000 shares of common stock are indirectly beneficially owned by the reporting person's spouse.
Stakeholder Impact
- Shareholders may observe a reduction in direct insider holdings, though this is part of a pre-planned strategy and not necessarily indicative of a change in management's confidence.
Key Dates
| Date | Description |
|---|---|
| 2019-08-09 | Grant date of the first non-qualified stock option, which is fully vested. |
| 2022-08-05 | Grant date of the second non-qualified stock option, which is fully vested. |
| 2025-09-04 | Date of stock option exercises and common stock sale transactions. |
| 2025-09-08 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
| 2029-08-09 | Expiration date of the non-qualified stock option with an exercise price of $3.15. |
| 2032-08-05 | Expiration date of the non-qualified stock option with an exercise price of $0.7063. |
Keywords
Aquestive Therapeutics, AQST, Cassie Jung, Chief Operating Officer, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.